Business context and reporting period
This Form 10-Q covers the three months ended March 31, 2021. The filing identifies the registrant as GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company—not Crescent Biopharma, Inc., as stated in the request metadata.
The company develops glycomimetic drug candidates and has no approved products or commercial drug sales. Its lead candidate, uproleselan, is in a Phase 3 trial for relapsed/refractory AML; other programs include GMI-1359 and preclinical GMI-1687.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | $1.1 million | $9.0 million |
| Research and development expense | $11.1 million | $12.7 million |
| General and administrative expense | $4.2 million | $4.4 million |
| Operating loss | $14.3 million | $8.1 million |
| Net loss | $14.3 million; $0.28 per share | $7.7 million; $0.18 per share |
| Cash used in operating activities | $14.1 million | $3.5 million |
| Cash and cash equivalents | $132.5 million at March 31, 2021 | $137.0 million at December 31, 2020 |
Revenue in Q1 2021 was from clinical supply sales to Apollomics. Q1 2020 revenue was the $9.0 million upfront payment under the Apollomics agreement. The company reported no gross margin measure; a meaningful product margin is not provided, given that it has no commercial drug sales.
Total assets were $138.0 million and total liabilities were $12.9 million at March 31, 2021. The filing reports no borrowings; liabilities included $2.6 million of operating lease obligations. Current assets of $133.7 million compared with current liabilities of $10.8 million. Cash declined by $4.6 million during the quarter, including $9.6 million of net proceeds from ATM stock sales. The company had 51.5 million shares outstanding at quarter-end, up from 49.0 million at December 31, 2020.
Material changes versus the prior comparable period
- Revenue decreased by $7.9 million, primarily because Q1 2020 included the Apollomics upfront payment while Q1 2021 revenue came from clinical supply sales.
- Net loss increased by $6.6 million despite lower operating expenses, as lower revenue and a $0.4 million decline in interest income more than offset expense reductions.
- R&D expense fell 12% to $11.1 million, mainly due to lower uproleselan clinical assay development and manufacturing costs. G&A expense decreased 6% to $4.2 million, primarily due to lower stock-based compensation.
- Operating cash use increased to $14.1 million from $3.5 million; the prior-year period included the $9.0 million Apollomics payment.
Outlook, risks and other notable items
- Management expected existing cash to fund operating expenses and capital requirements into the fourth quarter of 2022. A separate note says funds were expected to suffice for at least 12 months from the filing date. Both estimates depend on assumptions and spending and trial timing could cause cash to run out sooner.
- The company expects continuing operating losses and negative operating cash flows for the foreseeable future and may need additional capital. It warns that financing may not be available on acceptable terms; further equity issuance could dilute shareholders.
- Management expected to complete enrollment in the approximately 380-patient Phase 3 uproleselan trial by year-end 2021. COVID-19 previously slowed site initiation and enrollment; enrollment had returned to forecasted levels, but fluctuating infection rates could again affect enrollment and trial timing.
- Apollomics received Greater China rights to uproleselan and GMI-1687. GlycoMimetics may receive up to approximately $179 million in further milestones and tiered royalties, but payments depend on development and commercial outcomes and are uncertain.
- The company reported no material legal proceedings, no material changes to the risk factors in its 2020 Form 10-K, and no material changes in internal control over financial reporting. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Confirm the registrant identity: the supplied filing is GlycoMimetics, Inc., not Crescent Biopharma, Inc.
- Track Phase 3 uproleselan enrollment and timing, including any continuing impact from COVID-19, and review trial outcomes and regulatory developments.
- Monitor cash burn against the fourth-quarter 2022 runway estimate and assess the assumptions behind management’s funding outlook.
- Review further ATM sales, share-count changes and the remaining approximately $86.3 million capacity under the sales agreement as of March 31, 2021.
- Verify progress and potential milestone or royalty receipts under the Apollomics agreement; these are contingent and not assured.